Glaxo Group Limited

Smithkline Beecham (cork) Ltd

Glaxogrouplimited

Neurocrine, Inc.

Gabriella Gentile

Fabrizio Micheli

Silvia Terreni

Romano Di Fabio

Dieter Hamprecht

Giorgio Bonanomi

Giovanna Tedesco

Luca Tarsi

Anna Maria Capelli

Luca Arista

Anna Checchia

Federica Damiani

Barbara Bertani

Alessandra Pasquarello

Yves St Denis

Valeria Zucchelli

Adolfo Prandi

Dieter Wolfgang Hamprecht

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein

[object Object]

The present invention relates to certain azabicyclo compounds of formula (I)': wherein the various groups are defined herein and that are modulators of dopamine Dreceptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.

Compounds of formula (I) wherein A is a 5 or 6 membered heteroaromatic ring or a 5 or 6 membered heterocyclic ring, and which are useful for treating mental disorders such as schizophrenia are set out herein.

Compounds having affinity for dopamine D3 receptor and uses thereof

The invention provides 3-(methyloxy)-1-{4-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]butyl}-2(1H)-pyridinone of formula (I), or a pharmaceutically acceptable salt thereof.

Pyridinone derivative for the treatment of premature ejaculation

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: 

The present invention relates to novel compounds of formula (IA) or a salt thereof: wherein:

Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors

The present invention relates to novel compounds of formula (I) or a salt thereof: wherein: and P1 is and

Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine D3 receptors

The present invention relates to novel compounds of formula (I)' or a salt thereof: wherein and the other groups are define in herein.

Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, R, R, R, R, R, A, X, and Y are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

Growing community of inventors

Verona, Italy

Gabriella Gentile